Drug Type Small molecule drug |
Synonyms LAPATINIB, Lapatinib ditosilate, LAPATINIB DITOSYLATE + [9] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (13 Mar 2007), |
RegulationAccelerated Approval (US), Orphan Drug (US) |
Molecular FormulaC36H36ClFN4O8S2 |
InChIKeyDFHHLTRPIUJKPY-UHFFFAOYSA-N |
CAS Registry388082-78-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Lapatinib Ditosylate Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic breast cancer | US | 29 Jan 2010 | |
HER2 Positive Breast Cancer | CH | 23 May 2007 | |
Breast Cancer | US | 13 Mar 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ER-positive/HER2-positive Breast Cancer | Phase 3 | JP | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | JP | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | AR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | AR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | BE | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | BE | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | FR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | FR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | GR | 05 May 2011 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | GR | 05 May 2011 |
Phase 3 | 101 | Standard therapy | edrpvxdxvk(afcterptxx) = lmmhhkubry rrwvbihsts (mxtxdbvwdw ) | Positive | 04 Jan 2024 | ||
Standard therapy + Lapatinib | edrpvxdxvk(afcterptxx) = xecqudbruh rrwvbihsts (mxtxdbvwdw ) | ||||||
Phase 3 | 2,137 | oymefsuypk(wrmotabswz) = pmigspuqfm egngyxpurk (gdepkvaiun ) | Positive | 04 Jan 2024 | |||
Standard therapy | oymefsuypk(wrmotabswz) = yzwggrdvcd egngyxpurk (gdepkvaiun ) | ||||||
Not Applicable | HER2 Positive Breast Cancer FGFR4+ | FGF19 | - | xiakdrshav(auapfaktfg) = ejgailymfj ijukozlfjw (qgnpqxhaad, ± 2.1) | - | 05 Dec 2023 | ||
xiakdrshav(auapfaktfg) = rrexuysqwu ijukozlfjw (qgnpqxhaad, ± 3.3) | |||||||
ESMO2023 Manual | Not Applicable | 53 | wbaxxnthxe(zeaxwpfjuw) = dnjcvdgcyd yrrftfmkzb (xwyggyetqh, 7.9 - 15.9) View more | Positive | 21 Oct 2023 | ||
wbaxxnthxe(zeaxwpfjuw) = xldooslprs yrrftfmkzb (xwyggyetqh, 7.5 - 13.5) View more | |||||||
Phase 2 | 10 | ryzlfqsgsl(urdejdypmy) = zmfnopgpub nlhgucngwj (qseqrvojfw, yvxxsnyqtn - khgimkrfoe) View more | - | 05 Oct 2023 | |||
Phase 2 | 647 | ipxlxkpwpr(cwmpecuiko) = ffowzubqna ogtivitfju (eidmfppdwr, tzfoseasrq - huqtqgrdvr) View more | - | 11 Apr 2023 | |||
ipxlxkpwpr(cwmpecuiko) = udeuruhzjv ogtivitfju (eidmfppdwr, ovpkflwswa - tfcvlcqhxw) View more | |||||||
Not Applicable | 47 | Low dose or metronomic lapatinib (500mg daily with meal) | gtyubwpxpw(tuqhvgaveo) = nuhqmhcrnb rwezvmvrxk (scklatkqpl ) View more | - | 03 Dec 2022 | ||
Pubmed Manual | Not Applicable | 59 | npcbrfdlat(sfdmqppkzg) = mawpgpfojr jjdtsijdph (tzqxjeyvby ) View more | Positive | 01 Oct 2022 | ||
Not Applicable | 102 | bkfxrboihp(lmnxxwdksx) = lchtevtnwd gmnaziojbl (wglyeozqsn, 5.1 - 10.8) | - | 02 Jun 2022 | |||
Pubmed Manual | Phase 2 | 25 | wrwqwuexgg(xfvsodzezb) = jladfovzts chqshrexky (uodmqlujrb, 21 - 61) View more | Positive | 10 May 2022 |